The NORM Framework: Measuring Claim–Evidence Alignment in Consumer Brand Marketing
A structured methodology for evaluating whether consumer-facing marketing claims are proportionate to evidence publicly presented or cited by the brand
NORM’s assessment principles, evidence boundaries, scoring areas, verdict meanings, and limitations are publicly documented. Exact scoring weights, thresholds, model prompts, anti-gaming controls, and implementation details remain proprietary to preserve system integrity and prevent manipulation.
Consumer brand marketing operates under conditions of significant information asymmetry. This paper describes the NORM Framework (v1.1), a systematic methodology for evaluating whether consumer-facing marketing claims are proportionate to the evidence brands publicly present or cite. We describe the framework’s construct definition, evidence boundary rules, claim taxonomy, ten matching axes, six public score areas, claim-level verdict procedure, and the NORM Index that makes claim–evidence alignment measurable and comparable.
NORM evaluates representation, not reality. A score reflects what a brand publicly discloses, not what its products do — and in a market where consumer decisions are made almost entirely on what brands choose to show, that distinction is the point.
NORM is a gamified consumer product. Brands can improve their NORM Index by publishing stronger evidence, linking directly to relevant studies, aligning their claim language with what their evidence actually reports, or removing claims that exceed their evidence.
1. Purpose
NORM turns the distance between what a brand claims and what it publicly shows into a score people can understand and a record they can inspect.
The NORM Index is a 0–100 claim–evidence alignment index. Higher values indicate that a greater share of the brand’s important marketing claims aligns with evidence the brand publicly presents.
1.1 What NORM Measures
NORM compares consumer-facing marketing claims with evidence publicly presented or cited by the brand.
This is the complete scope. Every rule, score, and output derives from this comparison.
1.2 What NORM Does Not Measure
NORM does not determine:
- Whether a product works.
- Whether a product is safe.
- Whether a claim is legally compliant with FTC, FDA, or any regulatory standard.
- Whether the brand possesses private evidence it has not published.
- Whether the wider scientific literature ultimately supports or refutes a claim.
- Whether a consumer should purchase a product.
A high NORM Index means the brand’s public claims are well-supported by evidence the brand itself makes visible. It does not mean the product is effective, safe, or recommended.
2. The NORM Index
The NORM Index is a 0–100 alignment index derived from claim-level assessments. Higher values indicate that a greater share of the brand’s materially weighted claims aligns with evidence the brand publicly presents.
The Index is not a percentage. It is not an efficacy score. It is not a safety rating. It is not a legal compliance finding.
2.1 Rating Bands
The Index is accompanied by a rating band that provides interpretive context. Band boundaries are criterion-referenced — each corresponds to a substantive level of claim–evidence alignment, not a percentile of the assessed brand population.
2.2 Category Ranking
Brands are ranked within their category by NORM Index. Rankings reflect relative claim–evidence alignment within a category, not relative product quality or efficacy.
3. Six Score Areas
Every NORM assessment reports six diagnostic score areas. These help brands understand their strengths and weaknesses and identify opportunities for improvement.
Each area receives a diagnostic subscore. The overall NORM Index is not necessarily a simple average of the six areas. The Index is computed from claim-level assessments; the six areas provide a diagnostic decomposition.
4. Evidence Boundary
The evidence boundary is the single most important rule in the NORM framework.
4.1 Brand-Cited Sources
Evidence that the brand explicitly links, references by DOI or PMID, or identifiably cites on its consumer-facing pages.
4.2 NORM-Discovered Sources
Evidence found through NORM’s own research that is not linked or cited by the brand.
NORM-discovered sources may only authenticate a brand-provided citation, classify the cited paper, or assess its applicability.
5. Assessment Unit & Coverage
Under v1.1, NORM assesses a brand’s consumer-facing website as a whole. Each assessment reports pages assessed, capture date, methodology version, coverage, and confidence.
When NORM cannot capture sufficient content, the assessment is marked Incomplete. No score or rank is published.
6. Claim Categories
| Category | Example |
|---|---|
| Outcome / Efficacy | “Reduces cortisol by 40%” |
| Functional Benefit | “Supports gut health” |
| Mechanistic | “Works by activating AMPK pathway” |
| Composition / Dose | “Contains 600mg KSM-66 per serving” |
| Testing / Certification | “NSF Certified for Sport” |
| Superiority | “Most bioavailable form available” |
| Testimonial-Implied Outcome | A brand-published testimonial implying a health outcome |
| Puffery / Nonmaterial | “Premium quality” — excluded from scoring |
6.1 Materiality
Only material claims are scored. Puffery, navigation text, and extraction noise are excluded.
6.2 Testimonials
Brand-selected testimonials implying health outcomes are included. Purely subjective opinion and unfiltered third-party review feeds are excluded.
7. Claim-to-Evidence Matching
For each material claim, NORM assesses how well brand-cited evidence supports the claim across ten axes: product formulation match, population match, dose match, outcome match, duration match, study design appropriateness, reported result match, qualification match, risk of bias assessability, and language strength match.
Claim-to-Source Linkage
A source supports a claim when there is a direct citation, footnote, or hyperlink attached to the claim, or when the source appears on the same product or outcome page. A generic science page does not automatically support every claim.
8. Claim-Level Verdicts
9. Aggregation & Guardrails
A materially unsupported prominent claim cannot be hidden by averaging many well-supported claims. NORM applies a worst-material-claim guardrail. Its exact parameters are proprietary.
Every assessment publishes: total material claims assessed, count of Strong/Partial/Limited verdicts, the list of assessed claims with individual verdicts, and the six area subscores.
10. Score Movement & Gamification
Brands can improve their NORM Index by publishing stronger evidence, linking directly to relevant studies, aligning claim language with their evidence, or removing claims that exceed their evidence. Score movement over time is tracked and published.
11. Capture, Provenance & AI Processing
NORM captures brand website content using AI-assisted analysis with structured review and versioned assessment rules. Every assessment produces a permanent receipt. NORM’s software, prompts, and anti-manipulation systems are proprietary.
12. Validation Status
NORM v1.1 is operational and published assessments use the v1.1 methodology. Methodology validation is an ongoing process.
13. Limitations
- NORM assesses only what appears on a brand’s consumer-facing website at the time of capture.
- Claims in images and video are a known capture limitation.
- Small numerical score differences may not be meaningful.
- NORM does not assess private evidence, unpublished studies, or confidential regulatory filings.
- Low-confidence assessments are marked Incomplete and not ranked.
14. Corrections, Challenges & Appeals
Brands may challenge a NORM assessment. The correction process applies uniformly regardless of commercial relationship. All corrections are logged publicly.
15. Governance & Independence
NORM maintains governance controls to ensure scoring integrity. Commercial relationships do not influence assessment outcomes.
16. Version History
Legacy Round 1 — v1.0 (Archived)
NORM v1.0 used a six-dimension composite scoring model. v1.0 assessments are preserved as immutable Legacy Round 1 historical records. v1.0 is not the current NORM methodology. v1.0 and v1.1 scores are not directly comparable.
v1.1 — Current (Operational)
NORM v1.1 introduces claim-level assessment with ten matching axes, six diagnostic score areas, and a deterministic verdict procedure. v1.1 is the current operational methodology powering all published assessments.
Appendix A: Worked Example
Capture date: 2026-08-15 · Methodology: v1.1
Claim: “Clinically proven to reduce stress by 44%”
Location: Homepage hero banner · Type: Outcome/Efficacy · Materiality: High
Brand-Cited Source
A hyperlink to a published RCT (DOI: 10.xxxx/example) on the same product page. DOI resolves to a peer-reviewed journal article.
Ten-Axis Assessment
| Axis | Result | Reasoning |
|---|---|---|
| Product match | Partial | Key ingredient tested, not exact formulation |
| Population match | Partial | Adults 25–45 vs. “all adults” |
| Dose match | Direct | Study dose = product dose |
| Outcome match | Direct | Same perceived stress scale |
| Duration match | Direct | 60-day study matches use period |
| Study design | Appropriate | Double-blind placebo-controlled RCT |
| Result match | Partially supports | 29% reduction found, not 44% |
| Qualification match | Material omission | Subgroup-only effect omitted |
| Risk of bias | Low | Adequate randomization and blinding |
| Language match | Overstated | 44% claimed vs. 29% found, subgroup only |
Verdict: Partial Visible Alignment
The brand cites a relevant, well-designed study, but marketing language materially overstates the findings (44% vs. 29%) and omits a material limitation (subgroup effect).